{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:15:37Z","timestamp":1793445337312,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004863","name":"Zhejiang Chinese Medical University","doi-asserted-by":"publisher","award":["2025 Zhejiang Chinese Medical University Cultivation Plan for Top Innovative Talents of Postgraduates (No. 2025YJSBJ008)"],"award-info":[{"award-number":["2025 Zhejiang Chinese Medical University Cultivation Plan for Top Innovative Talents of Postgraduates (No. 2025YJSBJ008)"]}],"id":[{"id":"10.13039\/501100004863","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced colorectal cancer (CRC) predisposes to peritoneal metastases (PM), leading to a decreased survival rate. Advanced CRC includes CRC with PM (CRC-PM) and locally advanced high-risk CRC without PM. The effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) in prolonging survival and in treating or preventing PM after surgery for advanced CRC is still uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A search of PubMed, Cochrane, Embase, and Web of science databases for relevant studies prior to April 2024 was performed. Data were analyzed using Stata\/MP 17.0 software. The primary outcomes included overall survival (OS) and disease-free survival (DFS). Secondary outcomes were overall recurrence rate (ORR), PM rate, and complications. The quality of evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluations (GRADE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of ten high-quality cohort studies and four randomized controlled trials (RCTs) were included, encompassing 2851 patients. HIPEC improved 1-year DFS (odds ratio (OR)\u2009=\u20091.64, 95%Cl: 1.09\u20132.46) and 5-year OS (OR\u2009=\u20091.49, 95%Cl: 1.10\u20132.03) in advanced CRC. HIPEC also reduced the overall PM rate (OR\u2009=\u20090.66, 95%Cl: 0.49\u20130.90). For advanced high-risk CRC without prior PM, HIPEC reduced the PM rate and had a preventive effect (OR\u2009=\u20090.71, 95%Cl: 0.52\u20130.97). In terms of complications, HIPEC increased the incidence of thrombopenia (OR\u2009=\u20095.77, 95%Cl: 1.65\u201320.09) and neutropenia (OR\u2009=\u20093.21, 95%Cl: 1.74\u20135.90). The quality of evidence ranged from high to very low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of HIPEC in treating advanced CRC may result in improved survival rates and a reduction in peritoneal recurrence or metastasis, although complications should be considered. Further investigation is required to clarify the role of HIPEC in more high-quality RCTs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-025-04165-7","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:57:53Z","timestamp":1769695073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of hyperthermic intraperitoneal chemotherapy on patients with advanced colorectal cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Ziying","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Ru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoran","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaonan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fule","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"7","key":"4165_CR1","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/s2468-1253(22)00089-9","volume":"7","author":"M Song","year":"2022","unstructured":"Song M. Global epidemiology and prevention of colorectal cancer. Lancet Gastroenterol Hepatol. 2022;7(7):588\u201390. https:\/\/doi.org\/10.1016\/s2468-1253(22)00089-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"4165_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72(2):338\u201344. https:\/\/doi.org\/10.1136\/gutjnl-2022-327736.","journal-title":"Gut"},{"issue":"4","key":"4165_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3322\/caac.21728","volume":"72","author":"F Ciardiello","year":"2022","unstructured":"Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72(4):372\u2013401. https:\/\/doi.org\/10.3322\/caac.21728.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4165_CR4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.trecan.2019.12.008","volume":"6","author":"W Ceelen","year":"2020","unstructured":"Ceelen W, Ramsay RG, Narasimhan V, Heriot AG, De Wever O. Targeting the tumor microenvironment in colorectal peritoneal metastases. Trends Cancer. 2020;6(3):236\u201346. https:\/\/doi.org\/10.1016\/j.trecan.2019.12.008.","journal-title":"Trends Cancer"},{"issue":"3","key":"4165_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41416-024-02717-4","volume":"131","author":"C Ramos","year":"2024","unstructured":"Ramos C, Gerakopoulos V, Oehler R. Metastasis-associated fibroblasts in peritoneal surface malignancies. Br J Cancer. 2024;131(3):407\u201319. https:\/\/doi.org\/10.1038\/s41416-024-02717-4.","journal-title":"Br J Cancer"},{"issue":"10","key":"4165_CR6","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1007\/s00261-024-04451-0","volume":"49","author":"N Pisuchpen","year":"2024","unstructured":"Pisuchpen N, Lennartz S, Parakh A, Kongboonvijit S, Srinivas Rao S, Pierce TT, et al. Material density dual-energy CT images: value added in early diagnosis of peritoneal carcinomatosis: original research. Abdom Radiol (NY). 2024;49(10):3496\u2013506. https:\/\/doi.org\/10.1007\/s00261-024-04451-0.","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"4165_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/10717544.2020.1862364","volume":"28","author":"DR L\u00f6ke","year":"2021","unstructured":"L\u00f6ke DR, Helderman R, Franken NAP, Oei AL, Tanis PJ, Crezee J, et al. Simulating drug penetration during hyperthermic intraperitoneal chemotherapy. Drug Deliv. 2021;28(1):145\u201361. https:\/\/doi.org\/10.1080\/10717544.2020.1862364.","journal-title":"Drug Deliv"},{"issue":"8","key":"4165_CR8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamaoncol.2021.0580","volume":"7","author":"RM van Stein","year":"2021","unstructured":"van Stein RM, Aalbers AGJ, Sonke GS, van Driel WJ. Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer: A review. JAMA Oncol. 2021;7(8):1231\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0580.","journal-title":"JAMA Oncol"},{"issue":"11","key":"4165_CR9","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/bjs\/znad279","volume":"110","author":"A Arjona-S\u00e1nchez","year":"2023","unstructured":"Arjona-S\u00e1nchez A. In favour of prophylactic hyperthermic intraperitoneal chemotherapy for colorectal cancer. Br J Surg. 2023;110(11):1428\u201330. https:\/\/doi.org\/10.1093\/bjs\/znad279.","journal-title":"Br J Surg"},{"issue":"1","key":"4165_CR10","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1038\/s41598-022-06417-y","volume":"12","author":"X Zhuang","year":"2022","unstructured":"Zhuang X, He Y, Ma W. Prophylactic hyperthermic intraperitoneal chemotherapy May benefit the long-term survival of patients after radical gastric cancer surgery. Sci Rep. 2022;12(1):2583. https:\/\/doi.org\/10.1038\/s41598-022-06417-y.","journal-title":"Sci Rep"},{"issue":"9","key":"4165_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s1470-2045(20)30322-3","volume":"21","author":"D Go\u00e9r\u00e9","year":"2020","unstructured":"Go\u00e9r\u00e9 D, Glehen O, Quenet F, Guilloit JM, Bereder JM, Lorimier G, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020;21(9):1147\u201354. https:\/\/doi.org\/10.1016\/s1470-2045(20)30322-3.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4165_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1055\/s-0042-1758759","volume":"37","author":"R Shah","year":"2024","unstructured":"Shah R, Gangi A. Role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of colorectal peritoneal metastases. Clin Colon Rectal Surg. 2024;37(2):90\u20135. https:\/\/doi.org\/10.1055\/s-0042-1758759.","journal-title":"Clin Colon Rectal Surg"},{"issue":"4","key":"4165_CR13","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1245\/s10434-023-13100-7","volume":"30","author":"T Jastrzebski","year":"2023","unstructured":"Jastrzebski T, Colorectal Cancer T. Should prophylactic HIPEC be performed? Colorectal T4 HIPEC prophylactic. Ann Surg Oncol. 2023;30(4):2532\u20133. https:\/\/doi.org\/10.1245\/s10434-023-13100-7.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4165_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1245\/s10434-023-14368-5","volume":"31","author":"M H\u00fcbner","year":"2024","unstructured":"H\u00fcbner M, van Der Speeten K, Govaerts K, de Hingh I, Villeneuve L, Kusamura S, et al. 2022 peritoneal surface oncology group international consensus on HIPEC regimens for peritoneal malignancies: colorectal cancer. Ann Surg Oncol. 2024;31(1):567\u201376. https:\/\/doi.org\/10.1245\/s10434-023-14368-5.","journal-title":"Ann Surg Oncol"},{"key":"4165_CR15","unstructured":"Ziying Su XW, Xiaosong Ru Q, Mao N, Zhou Z, Xu L, Huang C, Ge, Yaonan Hong. Effect of hyperthermic intraperitoneal chemotherapy on patients with advanced colorectal cancer: a systematic review and meta-analysis. PROSPERO. 2024."},{"key":"4165_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4165_CR17","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008.","journal-title":"BMJ"},{"key":"4165_CR18","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"issue":"9","key":"4165_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"4165_CR20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/jso.23545","volume":"109","author":"CQ Huang","year":"2014","unstructured":"Huang CQ, Feng JP, Yang XJ, Li Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: a case-control study from a Chinese center. J Surg Oncol. 2014;109(7):730\u20139. https:\/\/doi.org\/10.1002\/jso.23545.","journal-title":"J Surg Oncol"},{"issue":"2","key":"4165_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/s1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, Go\u00e9r\u00e9 D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/s1470-2045(20)30599-4.","journal-title":"Lancet Oncol"},{"issue":"7","key":"4165_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","volume":"158","author":"A Arjona-S\u00e1nchez","year":"2023","unstructured":"Arjona-S\u00e1nchez A, Espinosa-Redondo E, Guti\u00e9rrez-Calvo A, Segura-Sampedro JJ, P\u00e9rez-Viejo E, Concepci\u00f3n-Mart\u00edn V, et al. Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer: A phase 3 randomized clinical trial. JAMA Surg. 2023;158(7):683\u201391. https:\/\/doi.org\/10.1001\/jamasurg.2023.0662.","journal-title":"JAMA Surg"},{"issue":"10","key":"4165_CR23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/s2468-1253(19)30239-0","volume":"4","author":"CEL Klaver","year":"2019","unstructured":"Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(10):761\u201370. https:\/\/doi.org\/10.1016\/s2468-1253(19)30239-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"4165_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/jco.22.02644","volume":"42","author":"ES Zwanenburg","year":"2024","unstructured":"Zwanenburg ES, El Klaver C, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): 5-Year results of a randomized multicenter trial. J Clin Oncol. 2024;42(2):140\u20135. https:\/\/doi.org\/10.1200\/jco.22.02644.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4165_CR25","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s00384-018-3146-z","volume":"33","author":"P Piso","year":"2018","unstructured":"Piso P, Stierstorfer K, Gerken M, Klinkhammer-Schalke M. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer. Int J Colorectal Dis. 2018;33(11):1559\u201367. https:\/\/doi.org\/10.1007\/s00384-018-3146-z.","journal-title":"Int J Colorectal Dis"},{"key":"4165_CR26","doi-asserted-by":"publisher","first-page":"959514","DOI":"10.3389\/fonc.2022.959514","volume":"12","author":"X Qin","year":"2022","unstructured":"Qin X, Siyad Mohamed M, Zhang Y, Chen Y, Wu Z, Luo R, et al. Hyperthermic intraperitoneal chemotherapy following up-front cytoreductive surgery versus cytoreductive surgery alone for isolated synchronous colorectal peritoneal metastases: A retrospective, observational study. Front Oncol. 2022;12:959514. https:\/\/doi.org\/10.3389\/fonc.2022.959514.","journal-title":"Front Oncol"},{"issue":"1","key":"4165_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12957-021-02320-4","volume":"19","author":"T Sun","year":"2021","unstructured":"Sun T, Li K, Xu G, Zhu K, Wang Q, Dang C, et al. Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis. World J Surg Oncol. 2021;19(1):200. https:\/\/doi.org\/10.1186\/s12957-021-02320-4.","journal-title":"World J Surg Oncol"},{"key":"4165_CR28","doi-asserted-by":"publisher","unstructured":"Guo X, Lin Y, Shen C, Li Y, Zeng X, Lv J, et al. Comparative study of Short-Term efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in colorectal cancer with T4 stage: A propensity score matching analysis. J Clin Med. 2023;12(3). https:\/\/doi.org\/10.3390\/jcm12031145.","DOI":"10.3390\/jcm12031145"},{"key":"4165_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2024.03.143","author":"T Mo","year":"2024","unstructured":"Mo T, Wen X, Hu T, Zhang Z, Shi Y, Chen Y, et al. The safety and effectiveness of prophylactic hyperthermic intraperitoneal chemotherapy in patients with pathological T3-4 locally advanced colon cancer. Asian J Surg. 2024. https:\/\/doi.org\/10.1016\/j.asjsur.2024.03.143.","journal-title":"Asian J Surg"},{"issue":"4","key":"4165_CR30","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/jso.27171","volume":"127","author":"SY Park","year":"2023","unstructured":"Park SY, Park JS, Kim HJ, Kim JG, Kang BW, Baek JH, et al. Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis. J Surg Oncol. 2023;127(4):668\u201377. https:\/\/doi.org\/10.1002\/jso.27171.","journal-title":"J Surg Oncol"},{"issue":"1","key":"4165_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1245\/s10434-016-5488-5","volume":"24","author":"D Baratti","year":"2017","unstructured":"Baratti D, Kusamura S, Iusco D, Gimondi S, Pietrantonio F, Milione M, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of primary curative surgery in patients with colorectal cancer at high risk for metachronous peritoneal metastases. Ann Surg Oncol. 2017;24(1):167\u201375. https:\/\/doi.org\/10.1245\/s10434-016-5488-5.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4165_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1245\/s10434-019-07935-2","volume":"27","author":"D Baratti","year":"2020","unstructured":"Baratti D, Kusamura S, Azmi N, Guaglio M, Montenovo M, Deraco M. Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without mitomycin C-Based HIPEC: A comparative study using the peritoneal surface disease severity score (PSDSS). Ann Surg Oncol. 2020;27(1):98\u2013106. https:\/\/doi.org\/10.1245\/s10434-019-07935-2.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"4165_CR33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10151-020-02270-1","volume":"25","author":"T Li","year":"2021","unstructured":"Li T, Yu J, Chen Y, Liu R, Li Y, Wang YX, et al. Preventive intraperitoneal hyperthermic perfusion chemotherapy for patients with T4 stage colon adenocarcinoma. Tech Coloproctol. 2021;25(6):683\u201391. https:\/\/doi.org\/10.1007\/s10151-020-02270-1.","journal-title":"Tech Coloproctol"},{"issue":"2","key":"4165_CR34","doi-asserted-by":"publisher","first-page":"107958","DOI":"10.1016\/j.ejso.2024.107958","volume":"50","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Zhang J, Chen C, Gong Z, Wang Z, Deng Q, et al. Prophylactic hyperthermic intraperitoneal chemotherapy in T4 colorectal cancer: can it improve the oncologic prognosis? - A propensity score matching study. Eur J Surg Oncol. 2024;50(2):107958. https:\/\/doi.org\/10.1016\/j.ejso.2024.107958.","journal-title":"Eur J Surg Oncol"},{"key":"4165_CR35","doi-asserted-by":"publisher","first-page":"107327482412845","DOI":"10.1177\/10732748241284535","volume":"31","author":"M He","year":"2024","unstructured":"He M, Li XD, Wang ZW, Sun H, Fan J. A retrospective observational study of hyperthermic intraperitoneal chemotherapy for gastric cancer and colorectal cancer from a single center in the recent 5 years. Cancer Control. 2024;31:10732748241284535. https:\/\/doi.org\/10.1177\/10732748241284535.","journal-title":"Cancer Control"},{"issue":"11","key":"4165_CR36","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1007\/s00262-023-03515-2","volume":"72","author":"J Kleber","year":"2023","unstructured":"Kleber J, Yang Zhou J, Weber F, Bitterer F, Hauer P, Kupke P, et al. Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy. Cancer Immunol Immunother. 2023;72(11):3867\u201373. https:\/\/doi.org\/10.1007\/s00262-023-03515-2.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4165_CR37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13046-024-03052-5","volume":"43","author":"L Varinelli","year":"2024","unstructured":"Varinelli L, Battistessa D, Guaglio M, Zanutto S, Illescas O, Lorenc EJ, et al. Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside. J Exp Clin Cancer Res. 2024;43(1):132. https:\/\/doi.org\/10.1186\/s13046-024-03052-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"4165_CR38","doi-asserted-by":"publisher","unstructured":"\u00d6zcan P, D\u00fczg\u00fcn \u00d6. The role of secondary cytoreduction and hyperthermic intraperitoneal chemotherapy in recurrent ovarian peritoneal carcinomatosis. J Pers Med. 2024;14(7). https:\/\/doi.org\/10.3390\/jpm14070742.","DOI":"10.3390\/jpm14070742"},{"issue":"8","key":"4165_CR39","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1097\/js9.0000000000000457","volume":"109","author":"M Patel","year":"2023","unstructured":"Patel M, Arora A, Mukherjee D, Mukherjee S. Effect of hyperthermic intraperitoneal chemotherapy on survival and recurrence rates in advanced gastric cancer: a systematic review and meta-analysis. Int J Surg. 2023;109(8):2435\u201350. https:\/\/doi.org\/10.1097\/js9.0000000000000457.","journal-title":"Int J Surg"},{"issue":"9","key":"4165_CR40","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.1245\/s10434-023-13757-0","volume":"30","author":"JH Gelissen","year":"2023","unstructured":"Gelissen JH, Adjei NN, McNamara B, Mutlu L, Harold JA, Clark M, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. Ann Surg Oncol. 2023;30(9):5597\u2013609. https:\/\/doi.org\/10.1245\/s10434-023-13757-0.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"4165_CR41","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/dcr.0000000000001156","volume":"61","author":"D Baratti","year":"2018","unstructured":"Baratti D, Kusamura S, Iusco D, Cotsoglou C, Guaglio M, Battaglia L, et al. Should a history of extraperitoneal disease be a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer peritoneal metastases? Dis Colon Rectum. 2018;61(9):1026\u201334. https:\/\/doi.org\/10.1097\/dcr.0000000000001156.","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"4165_CR42","first-page":"581","volume":"161","author":"M Ikeguchi","year":"1995","unstructured":"Ikeguchi M, Kondou A, Oka A, Tsujitani S, Maeta M, Kaibara N. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg. 1995;161(8):581\u20136.","journal-title":"Eur J Surg"},{"issue":"3","key":"4165_CR43","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1245\/s10434-022-12761-0","volume":"30","author":"BL Green","year":"2023","unstructured":"Green BL, Blumenthaler AN, Gamble LA, McDonald JD, Robinson K, Connolly M, et al. Cytoreduction and HIPEC for gastric carcinomatosis: Multi-institutional analysis of two phase II clinical trials. Ann Surg Oncol. 2023;30(3):1852\u201360. https:\/\/doi.org\/10.1245\/s10434-022-12761-0.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4165_CR44","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1186\/s12885-020-07339-6","volume":"20","author":"L Zhu","year":"2020","unstructured":"Zhu L, Xu Z, Wu Y, Liu P, Qian J, Yu S, et al. Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: a retrospective clinical study. BMC Cancer. 2020;20(1):827. https:\/\/doi.org\/10.1186\/s12885-020-07339-6.","journal-title":"BMC Cancer"},{"issue":"11","key":"4165_CR45","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamasurg.2023.3944","volume":"158","author":"JY Lee","year":"2023","unstructured":"Lee JY, Lee YJ, Son JH, Kim S, Choi MC, Suh DH, et al. Hyperthermic intraperitoneal chemotherapy after interval cytoreductive surgery for patients with Advanced-Stage ovarian cancer who had received neoadjuvant chemotherapy. JAMA Surg. 2023;158(11):1133\u201340. https:\/\/doi.org\/10.1001\/jamasurg.2023.3944.","journal-title":"JAMA Surg"},{"issue":"2","key":"4165_CR46","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10555-023-10158-3","volume":"43","author":"R Abedizadeh","year":"2024","unstructured":"Abedizadeh R, Majidi F, Khorasani HR, Abedi H, Sabour D. Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments. Cancer Metastasis Rev. 2024;43(2):729\u201353. https:\/\/doi.org\/10.1007\/s10555-023-10158-3.","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"4165_CR47","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ejso.2013.10.001","volume":"40","author":"YR van Gestel","year":"2014","unstructured":"van Gestel YR, Thomassen I, Lemmens VE, Pruijt JF, van Herk-Sukel MP, Rutten HJ, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol. 2014;40(8):963\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2013.10.001.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"4165_CR48","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1245\/s10434-017-6037-6","volume":"25","author":"CEL Klaver","year":"2018","unstructured":"Klaver CEL, van Huijgevoort NCM, de Buck A, Wolthuis AM, Tanis PJ, van der Bilt JDW, et al. Locally advanced colorectal cancer: true peritoneal tumor penetration is associated with peritoneal metastases. Ann Surg Oncol. 2018;25(1):212\u201320. https:\/\/doi.org\/10.1245\/s10434-017-6037-6.","journal-title":"Ann Surg Oncol"},{"key":"4165_CR49","doi-asserted-by":"publisher","first-page":"590452","DOI":"10.3389\/fsurg.2020.590452","volume":"7","author":"PY Zhao","year":"2020","unstructured":"Zhao PY, Hu SD, Li YX, Yao RQ, Ren C, He CZ, et al. Clinical efficacy and safety of hyperthermic intraperitoneal chemotherapy in colorectal cancer patients at high risk of peritoneal carcinomatosis: A systematic review and Meta-Analysis. Front Surg. 2020;7:590452. https:\/\/doi.org\/10.3389\/fsurg.2020.590452.","journal-title":"Front Surg"},{"issue":"8","key":"4165_CR50","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/cac2.12295","volume":"42","author":"AA Bhat","year":"2022","unstructured":"Bhat AA, Nisar S, Singh M, Ashraf B, Masoodi T, Prasad CP, et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: emerging avenue for targeted therapy. Cancer Commun (Lond). 2022;42(8):689\u2013715. https:\/\/doi.org\/10.1002\/cac2.12295.","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"4165_CR51","doi-asserted-by":"publisher","first-page":"e202100656","DOI":"10.1002\/cmdc.202100656","volume":"17","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Gao X, Yan B, Wen N, Lee WSV, Liang XJ, et al. Enhancement of CD8(+) T-Cell-Mediated tumor immunotherapy via magnetic hyperthermia. ChemMedChem. 2022;17(2):e202100656. https:\/\/doi.org\/10.1002\/cmdc.202100656.","journal-title":"ChemMedChem"},{"issue":"1","key":"4165_CR52","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejso.2021.08.027","volume":"48","author":"VJ Verwaal","year":"2022","unstructured":"Verwaal VJ, Funder JA, S\u00f8rensen MM, Iversen LH. The impact of postoperative complications following cytoreductive surgery combined with oxaliplatin based heated intraperitoneal chemotherapy. Eur J Surg Oncol. 2022;48(1):183\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2021.08.027.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"4165_CR53","doi-asserted-by":"publisher","first-page":"100586","DOI":"10.1016\/j.esmoop.2022.100586","volume":"7","author":"P Filis","year":"2022","unstructured":"Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open. 2022;7(5):100586. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100586.","journal-title":"ESMO Open"},{"issue":"7","key":"4165_CR54","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/jso.24248","volume":"113","author":"G Passot","year":"2016","unstructured":"Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N, et al. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures. J Surg Oncol. 2016;113(7):796\u2013803. https:\/\/doi.org\/10.1002\/jso.24248.","journal-title":"J Surg Oncol"},{"key":"4165_CR55","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jconrel.2024.07.017","volume":"373","author":"MT Perell\u00f3-Trias","year":"2024","unstructured":"Perell\u00f3-Trias MT, Serrano-Mu\u00f1oz AJ, Rodr\u00edguez-Fern\u00e1ndez A, Segura-Sampedro JJ, Ramis JM, Monjo M. Intraperitoneal drug delivery systems for peritoneal carcinomatosis: bridging the gap between research and clinical implementation. J Control Release. 2024;373:70\u201392. https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.017.","journal-title":"J Control Release"},{"issue":"10","key":"4165_CR56","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/bjs.11206","volume":"106","author":"I Ubink","year":"2019","unstructured":"Ubink I, Bolhaqueiro ACF, Elias SG, Raats DAE, Constantinides A, Peters NA, et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. Br J Surg. 2019;106(10):1404\u201314. https:\/\/doi.org\/10.1002\/bjs.11206.","journal-title":"Br J Surg"},{"issue":"14","key":"4165_CR57","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1158\/1078-0432.Ccr-20-0073","volume":"26","author":"V Narasimhan","year":"2020","unstructured":"Narasimhan V, Wright JA, Churchill M, Wang T, Rosati R, Lannagan TRM, et al. Medium-throughput drug screening of Patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy. Clin Cancer Res. 2020;26(14):3662\u201370. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0073.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4165_CR58","doi-asserted-by":"publisher","first-page":"442","DOI":"10.21037\/jgo-22-599","volume":"14","author":"I Prieto","year":"2023","unstructured":"Prieto I, Barb\u00e1chano A, Rodr\u00edguez-Salas N, Vi\u00f1al D, Cort\u00e9s-Guiral D, Mu\u00f1oz A, et al. Tailored chemotherapy for colorectal cancer peritoneal metastases based on a drug-screening platform in patient-derived organoids: a case report. J Gastrointest Oncol. 2023;14(1):442\u20139. https:\/\/doi.org\/10.21037\/jgo-22-599.","journal-title":"J Gastrointest Oncol"},{"issue":"9","key":"4165_CR59","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332. https:\/\/doi.org\/10.1245\/s10434-008-9966-2.","journal-title":"Ann Surg Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04165-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04165-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04165-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:21:07Z","timestamp":1781630467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04165-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4165"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04165-7","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}